Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lonasen (blonanserin) post-marketing safety and effectiveness surveillance in Chinese patients with schizophrenia
ChiCTR2100048734Phase 4Recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of blonanserin in schizophrenia, sponsored by The Second Xiangya Hospital. Primary endpoint: Incidence of adverse events. Started Jul 2021; status: recruiting.
02
Drugs
blonanserin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on ChiCTR2100048734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048734.